Julian Magadan, MD
Rheumatology · Kansas City, MONPI 1568660389
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,675 of the $3,215 with a category attached, or 83.2%. E.r. Squibb & Sons, L.L.C. accounts for 86.3% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $2,758, 8.7 times the $318 reported in 2019.
Across 40 payments — averaging $80.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$3K
- Amgen$206
- Novartis$109
- AbbVie$71
- Johnson & Johnson$24
- Genentech USA, Inc.$15
- plus $14 from 1 others
What the payments were for
- Consulting fees$2,67583%
- Food & beverage$54017%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 4 | $2,775 |
| Amgen(2 entities) | 22 | $206 |
| Novartis | 6 | $109 |
| AbbVie | 4 | $71 |
| Johnson & Johnson | 2 | $24 |
| Genentech USA, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$3,215 in reported general payments places this provider in the 60th percentile of 134 rheumatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 75 | $627,310 |
| Enbrel SureclickEtanercept | 25 | $387,192 |
| Humira(Cf)Adalimumab | 13 | $88,194 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $81,914 |
| OtezlaApremilast | 15 | $71,105 |
| Hydroxychloroquine Sulfate | 350 | $13,062 |
| MethotrexateMethotrexate Sodium | 518 | $12,779 |
| Mycophenolic AcidMycophenolate Sodium | 23 | $10,904 |
| Mycophenolate Mofetil | 54 | $7,299 |
| Celecoxib | 203 | $5,851 |
| Tramadol Hcl | 325 | $3,980 |
| Leflunomide | 73 | $3,110 |
| Sulfasalazine | 53 | $2,699 |
| Prednisone | 294 | $2,192 |
| Dapsone | 25 | $1,761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $71 | $88,19413 claims |
| AmgenOtezla | $206 | $71,10515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 134 rheumatology providers in Missouri.
Other rheumatology in Kansas City
- Mark BoxKansas City$304K
- Ghaith NoaisehKansas City$69K
- Thomas ScottKansas City$48K
- Tina ShahKansas City$36K
- David JohnKansas City$3K
- Anne WinklerCarthage$1.6M
- Adam KilianSaint Louis$565K
- Alfred KimSaint Louis$486K
- Sona KamatSaint Louis$268K
- Robert JacksonMemphis$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.